Bringing the peptide conversation to the public record.
Written submissions and public testimony are part of the Consortium’s reported FDA engagement.

Clear Health Pass submitted written comments to FDA Docket FDA-2025-N-6895 on July 9, 2026, supplemental comments on July 23 and public testimony in three sessions on July 23.
This is a company-reported participation history. Committee advice does not establish safety, efficacy or company program authorization.
A subsequent policy development
On October 30, 2026, the Federal Register published a notice of availability for a draft HHS enforcement-discretion policy regarding 503A compounding using certain peptide bulk drug substances. Its impact on company plans is under review.
Source: Federal Register 91 FR 68526, October 30, 2026.
HEAL WELL. AGE WELL. LIVE LONGER.